Inovio Pharmaceuticals, Inc. Logo Image

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. does not currently have any hardcopy reports on Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Inovio Pharmaceuticals, Inc.

51-200 Employees
Based in Plymouth Meeting, Pennsylvania

Inovio Pharmaceuticals is developing DNA immune therapies to prevent and treat cancers and infectious diseases. Our SynCon immunotherapies delivered using our proprietary electroporation technology have generated best-in-class immune responses, with therapeutic T-cells exceeding other technologies. In a phase II cervical dysplasia study, our DNA immune therapy induced regression of precancerous cervical disease and cleared HPV infection. Roche exclusively licensed Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol